Contrasting Pyxis Oncology (PYXS) & The Competition

Pyxis Oncology (NASDAQ:PYXS) is one of 844 public companies in the “Biotechnology” industry, but how does it weigh in compared to its competitors? We will compare Pyxis Oncology to related companies based on the strength of its earnings, risk, dividends, profitability, analyst recommendations, institutional ownership and valuation.

Volatility & Risk

Pyxis Oncology has a beta of 1.41, meaning that its share price is 41% more volatile than the S&P 500. Comparatively, Pyxis Oncology’s competitors have a beta of 1.12, meaning that their average share price is 12% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Pyxis Oncology and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pyxis Oncology	1	0	7	0	2.75
Pyxis Oncology Competitors	9828	15119	45430	1586	2.54

Pyxis Oncology presently has a consensus target price of $8.71, suggesting a potential upside of 424.96%. As a group, “Biotechnology” companies have a potential upside of 102.59%. Given Pyxis Oncology’s stronger consensus rating and higher probable upside, analysts clearly believe Pyxis Oncology is more favorable than its competitors.

Institutional & Insider Ownership

39.1% of Pyxis Oncology shares are held by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are held by institutional investors. 5.7% of Pyxis Oncology shares are held by company insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Pyxis Oncology and its competitors revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Pyxis Oncology	$13.86 million	-$79.62 million	-1.18
Pyxis Oncology Competitors	$691.14 million	$10.43 million	-15.00

Pyxis Oncology’s competitors have higher revenue and earnings than Pyxis Oncology. Pyxis Oncology is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Pyxis Oncology and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pyxis Oncology	N/A	-215.23%	-112.19%
Pyxis Oncology Competitors	-9,046.59%	-199.78%	-30.61%

Summary

Pyxis Oncology competitors beat Pyxis Oncology on 7 of the 13 factors compared.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.